The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for six CAR T cell therapies targeting BCMA and CD19 antigens in multiple myeloma and hematologic malignancies. This decision acknowledges established management guidelines and clinical experience mitigating cytokine release syndrome and neurotoxicity risks. Agency leaders and analysts hailed the move as a deregulatory step aimed at accelerating community adoption of these curative treatments and reducing provider burden. Additionally, the agency shortened patient post-treatment driving restrictions and medical facility stay requirements, reflecting growing confidence in cell therapy safety profiles.